A Single-Dose, Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneous LY2382770 in Japanese Patients With Chronic Kidney Disease
Phase of Trial: Phase I
Latest Information Update: 11 Oct 2010
At a glance
- Drugs LY 2382770 (Primary)
- Indications Diabetic nephropathies
- Focus Adverse reactions
- 11 Oct 2010 New trial record.